WASHINGTON — The Pentagon has removed Chinese biotech giant WuXi AppTec from its list of Chinese military companies, after a federal court blocked the designation, in a significant victory for one of the world’s largest drug-development contractors.

The removal, recorded in a government posting on Monday, November 9, 2026, ends — for now — a five-month fight that began when the Pentagon added WuXi AppTec to the Section 1260H list on June 8, 2026.

Key Points

• The Pentagon removed WuXi AppTec from its Section 1260H list of Chinese military companies on Monday, November 9, 2026.
• The Deputy Secretary of Defense acted because a federal court in Washington had blocked enforcement of the designation.
• WuXi AppTec joined the list on June 8, 2026, when the Pentagon expanded its blacklist to 188 entities, and sued three days later.
• On August 7, 2026, Chief Judge James Boasberg granted a preliminary injunction, finding WuXi AppTec likely to succeed.
• The removal is “without prejudice” to relisting, and the firm could still be named a “biotechnology company of concern” under the BIOSECURE Act.

What Happened

WuXi AppTec was removed from the Pentagon’s list of Chinese military companies in a government posting on Monday, November 9, 2026, Reuters reported. The Deputy Secretary of Defense acted because a federal court in Washington had blocked enforcement of the designation.

The move closes the latest chapter in a dispute that has put the Chinese contract research and manufacturing firm at the centre of Washington’s efforts to limit China’s access to American biotechnology and defence funding. WuXi AppTec is one of the largest companies of its kind in the world, serving drugmakers across the United States, Europe and Asia.

The Pentagon said the removal was “without prejudice to relisting the company on additional or supplementary grounds”, leaving the door open to a fresh designation. For now, the company is off the list.

Background: The June Blacklisting and the Lawsuit

WuXi AppTec was added to the Section 1260H list on June 8, 2026, when the Pentagon expanded its blacklist of Chinese military companies to 188 entities. The list, named for Section 1260H of the National Defense Authorization Act, names companies the Pentagon says are linked to China’s military. Inclusion does not itself make a company’s business illegal, but it bars the firm from Pentagon contracts and blocks customers from using US government funds on its projects.

Three days later, on June 11, 2026, WuXi AppTec sued in the US District Court for the District of Columbia, calling the designation arbitrary, capricious, unsupported by the facts and “the product of political pressure”. It argued the Pentagon had no proper basis for treating a civilian contract drugmaker as a military company.

On August 7, 2026, Chief Judge James Boasberg granted a preliminary injunction barring enforcement, finding WuXi AppTec was likely to succeed on the merits and was showing irreparable harm. The injunction left the designation formally on the books but stripped it of practical effect, setting up Monday’s removal.

WuXi AppTec and the Section 1260H List

The WuXi AppTec case has become the most closely watched test of the Section 1260H list, because it is one of the rare occasions on which a listed company has challenged the designation in court and won early relief.

WuXi AppTec’s success rested on the argument that the Pentagon had not shown its work. The company said the designation was unsupported by the facts, and Judge Boasberg’s finding that it was likely to succeed on the merits suggests the court was persuaded, at least at the preliminary stage, that the government’s evidence did not support the label.

Reactions and Quotes

WuXi AppTec’s lawsuit set out its position in blunt terms, calling the designation arbitrary, capricious and unsupported by the facts, and describing it as “the product of political pressure”. The company has maintained throughout that it is a civilian biotech services firm with no military role, and that the blacklisting punished it for US-China tensions rather than anything it had done.

Judge Boasberg’s August ruling gave the company its first clear win, finding it was likely to succeed on the merits and was suffering irreparable harm as customers terminated or paused work. The Pentagon, in removing the company, offered no concession that the original designation was wrong, and its “without prejudice” language signals it may try again with a different justification.

Why It Matters

The removal matters first for WuXi AppTec and its customers. With the designation lifted, the company can again compete for Pentagon contracts, and its customers can again use US government funds on its projects without fear of the blacklist. That should steady a business that has spent five months defending its reputation in court.

It also matters for the rest of the Section 1260H list: the injunction shows listed companies can challenge their designations and win when the government’s evidence is thin. The case also shows the tension in US policy toward China’s biotech sector, where American drugmakers rely on Chinese contract firms and a blunt blacklisting can disrupt the development of medicines too.

What Happens Next

The most immediate question is whether the Pentagon will try to relist WuXi AppTec on new grounds. Its “without prejudice” language keeps that option open, and the department could return with a fresh designation built on different evidence. Any new attempt would face the same court and would need to be stronger than the one Judge Boasberg blocked.

A second, separate threat remains. WuXi AppTec could still be named a “biotechnology company of concern” under the BIOSECURE Act, which would restrict federal contracts with named biotech firms. That list is expected by December 18, 2026.

Frequently Asked Questions

Why was WuXi AppTec removed from the Pentagon list?

The Deputy Secretary of Defense ordered the removal because a federal court in Washington had enjoined the department from enforcing the designation. Chief Judge James Boasberg granted a preliminary injunction on August 7, 2026, finding WuXi AppTec was likely to succeed and faced irreparable harm.

What is the Section 1260H list?

It is the Pentagon’s list of Chinese military companies, named for Section 1260H of the National Defense Authorization Act. Inclusion bars Pentagon contracts and blocks customers from using US government funds on its projects. WuXi AppTec was added on June 8, 2026, when the list was expanded to 188 entities.

Can the Pentagon put WuXi AppTec back on the list?

Yes. The Pentagon said the removal was “without prejudice to relisting the company on additional or supplementary grounds”, so it could try again with a different justification.

What is the BIOSECURE Act threat?

WuXi AppTec could still be named a “biotechnology company of concern” under the BIOSECURE Act, which would restrict federal contracts with the firm. The Office of Management and Budget is expected to publish that list by December 18, 2026.

What does this mean for WuXi AppTec’s US business?

With the designation lifted, the company can again seek Pentagon contracts and its customers can use US government funds on its projects, removing a cloud over its American operations.

Related reading: China Extends Suspension of 24% Tariff on US Imports • China Confirms Xi-Trump-Putin Meeting Talks • Nvidia Board Launches Probe of CEO Jensen Huang